On December 7, 2024, Canurta Therapeutics participated in the 35th International Symposium on ALS/MND, hosted by the Motor Neurone Disease (MND) Association. This event provided an opportunity to present research findings and engage with the global ALS community.
The poster presentation, "IVV-40: Therapeutic Potential of Cannabis-Derived Formulations in Mitigating Motor Neuron Disease," highlighted findings from Canurta’s CNR-400s series. These standardized botanical formulations, which combine polyphenols, cannabinoids, and terpenes, were evaluated in models of ALS and frontotemporal dementia. Results suggest potential benefits in enhancing motor function and supporting neuronal health through targeting multiple disease pathways.
The research abstract is available under Theme 04, page 22, offering detailed insights into these findings and their implications for ALS treatment.
Access the research abstract here:
Comments